Altair Engineering's ROCE trend is concerning, having declined over the past five years. Despite this, the stock has yielded a 124% return to long-term shareholders, reflecting market optimism. However, if these trends continue, it may not be a multi-bagger in the future.
Altair Engineering's high P/S ratio may not be justified due to weak revenue forecasts. This could pose a risk to shareholders and potential investors as it may negatively impact the share price.
Altair Engineering's revenue growth, reflected in its rising share price, is the market's focus due to lack of profits. Recent positive sentiment suggests potential business momentum.
$Altair Engineering(ALTR.US)$low Reward/Risk ratio not interested here. hit hard several stonks panic buying not considering R/R ratio . No more emotions attached to fear of missing plays in market. always careful 👍🏻
The recent selling of shares by insiders at Altair Engineering, without any recorded purchases, may raise concerns among shareholders. Despite the high level of insider ownership, the lack of buying activity does not inspire confidence in the company's prospects.
Investors: monitor for potential price drop due to current overvaluation. Current timing may not be ideal for entry due to surpassing of true value. However, optimistic outlook suggests looking into other factors for next price drop.
Upgrades •$Carvana(CVNA.US)$: Raymond James Upgrades to Market Perform from Underperform •$紐曼礦業(NEM.US)$: Canaccord Upgrades to Buy from Hold - PT $66 (from $60) •$印北瓦電(NI.US)$: Edward Jones Upgrades to Buy from Hold •$斯倫貝謝(SLB.US)$: Benchmark Upgrades to Buy from Hold - PT $55 Downgrades •$阿吉賽斯(AGYS.US)$: Craig-Hallum Downgrades to Hold from Buy •$克利夫蘭克里夫(CLF.US)$: GLJ Research Downgrades t...
Gainers: •$Axsome Therapeutics(AXSM.US)$+39.1% (received from FDA proposed labeling for the its AXS-05 product candidate with respect to its New Drug Application for AXS-05 for the treatment of major depressive disorder) •$Capricor Therapeutics(CAPR.US)$+4% (announces statistically significant clinical benefits in skeletal muscle function in non-ambulant duchenne muscular dystrophy patients treated with CAP-1002 in HOPE-2 Open L...
Altair Engineering股票討論區
專欄Top upgrades and downgrades on 7/27: MCD, SHOP, SLB, LOGI and more
• $Carvana(CVNA.US)$ : Raymond James Upgrades to Market Perform from Underperform
• $紐曼礦業(NEM.US)$ : Canaccord Upgrades to Buy from Hold - PT $66 (from $60)
• $印北瓦電(NI.US)$ : Edward Jones Upgrades to Buy from Hold
• $斯倫貝謝(SLB.US)$ : Benchmark Upgrades to Buy from Hold - PT $55
Downgrades
• $阿吉賽斯(AGYS.US)$ : Craig-Hallum Downgrades to Hold from Buy
• $克利夫蘭克里夫(CLF.US)$ : GLJ Research Downgrades t...
專欄Today's pre-market stock movers: BNTX, JBLU, DWAC, SAVE and more
• $Axsome Therapeutics(AXSM.US)$ +39.1% (received from FDA proposed labeling for the its AXS-05 product candidate with respect to its New Drug Application for AXS-05 for the treatment of major depressive disorder)
• $Capricor Therapeutics(CAPR.US)$ +4% (announces statistically significant clinical benefits in skeletal muscle function in non-ambulant duchenne muscular dystrophy patients treated with CAP-1002 in HOPE-2 Open L...
專欄Top upgrades and downgrades on 6/27: ETSY, CHWY, BBBY, GTLB and more
• $汽車地帶(AZO.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $2,296 (from $1,969)
• $Chewy(CHWY.US)$ : Needham Upgrades to Buy from Hold - PT $55
• $National Vision(EYE.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $32 (from $31)
• $費森尤斯醫療(FMS.US)$ : Jefferies Upgrades to Buy from Underperform - PT $33.70 (from $30.30)
• $Gitlab(GTLB.US)$ : Goldman Sachs Upgrades to Buy from Neutral - ...
專欄Top upgrades and downgrades on 11/05
By Mia
$Redbox Entertainment(RDBX.US)$$Altair Engineering(ALTR.US)$$加拿大貝爾(BCE.US)$$思佳訊(SWKS.US)$$再生元製藥公司(REGN.US)$
暫無評論